We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Leonard, BE. Editorial: Litigation and the toxicity of psychotropic drugs. Ir J Psychol Med1996; 13:88–9CrossRefGoogle Scholar
2
2.Casey, P. Commentary: Litigation and the toxicity of psychotropic drugs. Ir J Psychol Med1996; 13:89–90CrossRefGoogle Scholar
3
3.Carlston, A, Allebeck, P, Brandt, L. Are suicide rates in Sweden associated with changes in the prescribing of medicines?Acta Psychiat Scand1996; 94: 94–100.CrossRefGoogle Scholar
4
4.Farmer, RDT. Suicide and poisons. Human Psychopharmac1994; 9(1): S1–S21.CrossRefGoogle Scholar
5
5.Henry, JA, Alexander, CA, Sener, EK. Relative mortality from overdose of antidepressives. BMJ1995; 310: 221–4.CrossRefGoogle Scholar
6
6.Daly, RJ. Medico-legal aspects of prescribing. Human Psychopharmac1994; 9(1):S31–S36.CrossRefGoogle Scholar
7
7.de Gier, JJ. Drugs other than alcohol and driving in the European Union. Study coordinated with the support of the European Blood Safety Federation and the Directorate General for Transport of the Commission for the European Communities. EC document 1995; IHP: 95–94.Google Scholar
8
8.Ray, WA, Fought, RL, Decker, MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol1992; 16: 873–83.CrossRefGoogle Scholar
9
9.Montgomery, SA, Henry, JA, McDonald, G, et al.Selective serotonin re-uptake inhibitors: meta analysis of discontinuation rates. Int Clin Psychopharmac1994; 9: 47–53.CrossRefGoogle Scholar